BCRX Relative Valuation
BCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCRX is overvalued; if below, it's undervalued.
Historical Valuation
BioCryst Pharmaceuticals Inc (BCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.48 is considered Undervalued compared with the five-year average of -32.08. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 128.77 to 153.83 according to relative valuation methord. Compared to the current price of 7.92 USD , BioCryst Pharmaceuticals Inc is Undervalued By 93.85%.
Relative Value
Fair Zone
128.77-153.83
Current Price：7.92
93.85%
Undervalued
31.75
PE
1Y
3Y
5Y
22.73
EV/EBITDA
BioCryst Pharmaceuticals Inc. (BCRX) has a current EV/EBITDA of 22.73. The 5-year average EV/EBITDA is -7.74. The thresholds are as follows: Strongly Undervalued below -133.05, Undervalued between -133.05 and -70.39, Fairly Valued between 54.92 and -70.39, Overvalued between 54.92 and 117.58, and Strongly Overvalued above 117.58. The current Forward EV/EBITDA of 22.73 falls within the Historic Trend Line -Fairly Valued range.
17.30
EV/EBIT
BioCryst Pharmaceuticals Inc. (BCRX) has a current EV/EBIT of 17.30. The 5-year average EV/EBIT is 10.20. The thresholds are as follows: Strongly Undervalued below -117.17, Undervalued between -117.17 and -53.49, Fairly Valued between 73.88 and -53.49, Overvalued between 73.88 and 137.56, and Strongly Overvalued above 137.56. The current Forward EV/EBIT of 17.30 falls within the Historic Trend Line -Fairly Valued range.
2.48
PS
BioCryst Pharmaceuticals Inc. (BCRX) has a current PS of 2.48. The 5-year average PS is 6.41. The thresholds are as follows: Strongly Undervalued below -3.41, Undervalued between -3.41 and 1.50, Fairly Valued between 11.31 and 1.50, Overvalued between 11.31 and 16.22, and Strongly Overvalued above 16.22. The current Forward PS of 2.48 falls within the Historic Trend Line -Fairly Valued range.
24.12
P/OCF
BioCryst Pharmaceuticals Inc. (BCRX) has a current P/OCF of 24.12. The 5-year average P/OCF is -12.46. The thresholds are as follows: Strongly Undervalued below -72.51, Undervalued between -72.51 and -42.48, Fairly Valued between 17.57 and -42.48, Overvalued between 17.57 and 47.60, and Strongly Overvalued above 47.60. The current Forward P/OCF of 24.12 falls within the Overvalued range.
14.00
P/FCF
BioCryst Pharmaceuticals Inc. (BCRX) has a current P/FCF of 14.00. The 5-year average P/FCF is 1.68. The thresholds are as follows: Strongly Undervalued below -159.36, Undervalued between -159.36 and -78.84, Fairly Valued between 82.19 and -78.84, Overvalued between 82.19 and 162.71, and Strongly Overvalued above 162.71. The current Forward P/FCF of 14.00 falls within the Historic Trend Line -Fairly Valued range.
BioCryst Pharmaceuticals Inc (BCRX) has a current Price-to-Book (P/B) ratio of -4.07. Compared to its 3-year average P/B ratio of -3.66 , the current P/B ratio is approximately 11.16% higher. Relative to its 5-year average P/B ratio of -13.42, the current P/B ratio is about -69.66% higher. BioCryst Pharmaceuticals Inc (BCRX) has a Forward Free Cash Flow (FCF) yield of approximately 3.03%. Compared to its 3-year average FCF yield of -5.44%, the current FCF yield is approximately -155.75% lower. Relative to its 5-year average FCF yield of -6.05% , the current FCF yield is about -150.13% lower.
-4.07
P/B
Median3y
-3.66
Median5y
-13.42
3.03
FCF Yield
Median3y
-5.44
Median5y
-6.05
Competitors Valuation Multiple
The average P/S ratio for BCRX's competitors is 170.20, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX) exhibits a P/S ratio of 2.48, which is -98.54% above the industry average. Given its robust revenue growth of 36.14%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BCRX increased by 0.25% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -71.46 to -165.49.
The secondary factor is the Revenue Growth, contributed 36.14%to the performance.
Overall, the performance of BCRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is BioCryst Pharmaceuticals Inc (BCRX) currently overvalued or undervalued?
BioCryst Pharmaceuticals Inc (BCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.48 is considered Undervalued compared with the five-year average of -32.08. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 128.77 to 153.83 according to relative valuation methord. Compared to the current price of 7.92 USD , BioCryst Pharmaceuticals Inc is Undervalued By 93.85% .
What is BioCryst Pharmaceuticals Inc (BCRX) fair value?
BCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 128.77 to 153.83 according to relative valuation methord.
How does BCRX's valuation metrics compare to the industry average?
The average P/S ratio for BCRX's competitors is 170.20, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX) exhibits a P/S ratio of 2.48, which is -98.54% above the industry average. Given its robust revenue growth of 36.14%, this premium appears sustainable.
What is the current P/B ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jan 09 2026?
As of Jan 09 2026, BioCryst Pharmaceuticals Inc (BCRX) has a P/B ratio of -4.07. This indicates that the market values BCRX at -4.07 times its book value.
What is the current FCF Yield for BioCryst Pharmaceuticals Inc (BCRX) as of Jan 09 2026?
As of Jan 09 2026, BioCryst Pharmaceuticals Inc (BCRX) has a FCF Yield of 3.03%. This means that for every dollar of BioCryst Pharmaceuticals Inc’s market capitalization, the company generates 3.03 cents in free cash flow.
What is the current Forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jan 09 2026?
As of Jan 09 2026, BioCryst Pharmaceuticals Inc (BCRX) has a Forward P/E ratio of 31.75. This means the market is willing to pay $31.75 for every dollar of BioCryst Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jan 09 2026?
As of Jan 09 2026, BioCryst Pharmaceuticals Inc (BCRX) has a Forward P/S ratio of 2.48. This means the market is valuing BCRX at $2.48 for every dollar of expected revenue over the next 12 months.